Contents Link Navigation Link
PIPELINE

Targeting, Attacking, and Eradicating Cancers®

Development Pipeline

Targeting, Attacking, and Eradicating Cancers®

PRECLINICAL
CLINICAL (PEXA-VEC, JX-594)
PHASE I
  • PEXA-VEC + LIBTAYO®
    Advanced Renal Cell Carcinoma
  • PEXA-VEC + IMFINZI(+ tremlimumab)®Colorectal Cancer 2L/3L
  • nih
  • PEXA-VEC + OPDIVO®Liver Cancer
  • transgene
  • PEXA-VEC + YERVOY®Solid Tumors
  • transgene
  • PEXA-VEC (neoadjuvant)Solid Tumors
  • transgene
  • PEXA-VEC + PD-L1Liver Cancer
  • pharm
  • SillaJen-proprietary assets (Unpartnered with full global rights intact)
  • SillaJen is global sponsor
  • Transgene-sponsored study
  • PI-sponsored study
  • Lee’s Pharma-sponsored study